| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603282 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(13 years from now) | |
| US10842751 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(13 years from now) | |
Delstrigo is owned by Msd Merck Co.
Delstrigo contains Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate.
Delstrigo has a total of 3 drug patents out of which 0 drug patents have expired.
Delstrigo was authorised for market use on 30 August, 2018.
Delstrigo is available in tablet;oral dosage forms.
Delstrigo can be used as treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to the individual components of delstrigo; for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed.
Drug patent challenges can be filed against Delstrigo from 2022-08-30.
The generics of Delstrigo are possible to be released after 29 November, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 30, 2023 |
| New Patient Population (NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
NCE-1 date: 2022-08-30
Market Authorisation Date: 30 August, 2018
Treatment: Treatment of hiv-1 infection in adult patients as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to...
Dosage: TABLET;ORAL
DELSTRIGO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic